AIDS Clinical Trials Group

The AIDS Clinical Trials Group (ACTG) is the largest HIV clinical trials organization in the world, playing a major role in setting standards of care for HIV infection and opportunistic diseases related to HIV and AIDS in the United States and the developed world. The ACTG is composed of, and directed by, leading clinical scientists in HIV/AIDS therapeutic research. The ACTG is funded by the Department of Health and Human Services, National Institutes of Health through the National Institute of Allergy and Infectious Diseases.

Additional recommended knowledge

Daily Sensitivity Test

Don't let static charges disrupt your weighing accuracy

What is the Correct Way to Check Repeatability in Balances?

Mission

Through innovative studies of the treatment of HIV-1 infection and its complications, ACTG research focuses on:

• New therapies based on knowledge of the cellular events and reactions in the development of disease (pathogenesis)
• Treatment strategies to limit replication of HIV-1 and improve disease-free survival among infected individuals
• Rapid development of agents (drugs or treatments) that prevent or delay the complications of HIV-related disorders
• HIV-1 pathogenesis through advanced laboratory investigation
• Recruitment and retention of clinical trial participants who reflect the changing demographics of the AIDS epidemic
• Therapeutic approaches that improve quality of life for persons with HIV-1 infection

History

The ACTG has been pivotal in providing the data necessary for the approval of therapeutic agents, as well as the treatment and prevention strategies, for many opportunistic infections and malignancies.

In 1986 the original AIDS Treatment and Evaluation Units were established by the National Institutes of Health.

In 1987, the AIDS Clinical Trials Group (ACTG) was established by the National Institute of Allergy and Infectious Diseases

In 1991 the ACTG split to create the Adult ACTG (AACTG) and the Pediatric ACTG (PACTG)

In 1995 the AACTG restructured and created a true self-government structure, with self-evaluation of sites, priority setting of scientific research, discretionary spending. The PACTG became its own group and an AIDS Malignancy Consortium was established under the National Cancer Institute.

In 1999 the AACTG applied for continued funding as an investigator led and run group

In 2000 the AACTG began the planning and development of international research initiatives in the developing world

Scientific Accomplishments

• Integral involvement in new antiretroviral drug development: AZT, ddC, ddI, d4T, nevirapine, delavirdine, indinavir, amprenavir, ritonavir
• Established standards for evaluation of combination antiretroviral therapy with Nucleoside reverse transcriptase inhibitors and Protease inhibitors

Strategies for sequencing of regimens or enhancing their activity

Evaluation of approaches to salvage therapy

Evaluation of novel immune-based therapies using interferons, GM-CSF, G-CSF, thalidomide, IL-2, IL-12, ciclosporin (CsA), prednisone, cytotoxic agents, therapeutic immunization

• Evaluation of pharmacokinetics of novel agents and important drug interactions
• Established standard of care for treatment and prevention of HIV-1 associated opportunistic complications:

Pneumocystis carinii pneumonia

CMV retinitis

Cryptococcal meningitis

Toxoplasmic encephalitis

Hepatitis B and Hepatitis C

Histoplasmosis

Herpes virus infections

Mycobacterium avium complex disease

Tuberculosis

• Established standard of care for treatment of HIV-1 associated malignancies
• Evaluation of neurologic complications of HIV/AIDS - dementia, sensory neuropathy